Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

15.990
-0.510-3.09%
Volume:5.74M
Turnover:91.72M
Market Cap:42.52B
PE:10.79
High:16.480
Open:16.480
Low:15.800
Close:16.500
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:0.99
T/O Rate:1.06%
Dividend:0.46
Dividend Rate:2.85%
EPS(LYR):1.482
ROE:6.95%
ROA:1.40%
PB:0.75
PE(LYR):10.79
PS:0.86

Loading ...

FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News
·
Apr 14

Hong Kong Market Announcement Highlights: VGT Launches IPO with CPE Rosewood and Janchor Fund as Cornerstone Investors

Stock News
·
Apr 13

BRIEF-Shanghai Fosun Pharma Unit's Drug Registration Application For Flurbiprofen Axetil Injection Approved By NMPA

Reuters
·
Apr 10

FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization

Stock News
·
Apr 10

Shanghai Fosun Pharma - Unit's Drug Registration Application for Flurbiprofen Axetil Injection Approved by Nmpa

THOMSON REUTERS
·
Apr 10

Fosun Pharma Schedules 28 April Board Meeting to Review Q1 2026 Results

Bulletin Express
·
Apr 10

Fosun Pharmaceutical Names CFO

MT Newswires Live
·
Apr 03

Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug

MT Newswires Live
·
Apr 02

FOSUN PHARMA Subsidiary Receives Clinical Trial Approval for HLX319 Drug

Stock News
·
Apr 01

Fosun Pharmaceutical to Set Up Parallel Fund Structure

MT Newswires Live
·
Apr 01

Fosun Pharma Unit Gets China Nod for Tumor Drug Trial

MT Newswires Live
·
Mar 31

Fosun Pharma Subsidiary Secures NMPA Approval to Launch Phase I Trial of FXB0871 for Advanced Solid Tumors

Bulletin Express
·
Mar 31

BRIEF-Shanghai Fosun Pharma Announces Approval From NMPA For Clinical Trial Of FXB0871

Reuters
·
Mar 31

Shanghai Fosun Pharma - Approval From Nmpa for Clinical Trial of Fxb0871

THOMSON REUTERS
·
Mar 31

FOSUN PHARMA Reports 2025 Results: Revenue Hits 41.7B Yuan with 21.7% Net Profit Growth

Deep News
·
Mar 25

FOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan

Deep News
·
Mar 25

Stock Track | Fosun Pharma Soars 5.21% Intraday on Strong 2025 Earnings and Dividend Announcement

Stock Track
·
Mar 25

FOSUN PHARMA Declares Final Dividend of HK$0.39 Per Share

Stock News
·
Mar 25

Fosun Pharma Announces RMB0.39 Final Dividend for FY2025

Bulletin Express
·
Mar 25

Fosun Pharma 2025 Results: Net Profit Up 21.69%, Innovative-Drug Sales Surge 29.59%

Bulletin Express
·
Mar 25